Investigational drug · Phase 3
Blinded Envudeucitinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Plaque Psoriasis, Psoriasis (PsO), Psoriasis.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Blinded Envudeucitinib"
First trial start
2025
Jan 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Blinded Envudeucitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- Psoriasis (PsO)
- Psoriasis
- Moderate Psoriasis
- Severe Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Blinded Envudeucitinib" as an intervention, largest first.
- Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Alumis IncIndustry
NCT06846541 · 1,680 participants (planned) · Start Jan 8, 2025 · Primary completion Nov 2028
Drug: Open-Label Envudeucitinib; Blinded Envudeucitinib and 1 more · For: Plaque Psoriasis; Psoriasis (PsO); Psoriasis and 2 more
Sites: Birmingham, Alabama; Chandler, Arizona; Pheonix, Arizona · 268 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.